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Abstract
Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health
Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased risk for the
development of MNs, mainly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Setting the diagnosis of MN with
germline predisposition is of crucial clinical significance since it may tailor therapy, dictate the selection of donor for allogeneic
hematopoietic stem cell transplantation (allo-HSCT), determine the conditioning regimen, enable relevant prophylactic measures and
early intervention or contribute to avoid unnecessary or even harmful medication. Finally, it allows for genetic counseling and follow-up
of at-risk family members. Identification of these patients in the clinical setting is challenging, as there is no consensus due to lack of
evidence regarding the criteria defining the patients who should be tested for these conditions. In addition, even in cases with a strong
suspicion of a MN with germline predisposition, no standard diagnostic algorithm is available. We present the first version of the
Nordic recommendations for diagnostics, surveillance and management including considerations for allo-HSCT for patients and
carriers of a germline mutation predisposing to the development of MNs.his study was supported by grants form the Nordic Cancer Union (NCU).
he authors declare no conflicts of interest.
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1 Excessive toxicities with chemotherapy or radiation, multiple cancer diagnoses,
therapy-related leukaemia, poor stem cell mobilization of a sibling candidate donor
(reported in rare cases related to TERC and RUNX1 germline variants)27,39,
consanguinity, skin or nail abnormalities, unexplained liver disease, pulmonary
fibrosis or alveolar proteinosis, short stature, microcephaly or characteristic skeletal
abnormalities or other congenital abnormalities, Café au lait spots, hypopigmented
macules, lymphedema, immune deficiencies, atypical infections, excessive warts
(Table 1).
2 other haematological malignancies or cancer forms suggestive of constitutional
mismatch repair deficiency syndrome, Li-Fraumeni syndrome, BRCA2 related
syndromes (such as sarcomas, adrenocortical carcinomas, brain tumours,
gastrointestinal, genitourinary, breast, ovarian and pancreas cancer). It should
be noted that a number of conditions included in criterion A may appear with
atypical or no clinical stigmata, therefore a detailed personal and family history
including a three generations pedigree is needed. In order to facilitate the obtainment
of such a history a questionnaire proposed by Churpek et al.30 from the Chicago
group could be used.
P. Baliakas et al. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in AdultsIntroduction
Although the majority of myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML) cases are sporadic, the introduc-
tion of next-generation sequencing (NGS) into the diagnostic
work-up has revealed that hereditary MDS or AML are more
common than previously thought. Estimates suggest that about
5% to 15% of adults and 4% to 13% of pediatric patients with
MDS or AML carry germline pathogenic variants in cancer
susceptibility genes.1–4 At the same time, several new genes
associated with familial MDS or AML, with or without
syndromic features, have been recently discovered, such as
GATA2, ETV6, DDX41, SAMD9, and SAMD9L.5–20
In 2016, myeloid neoplasms with germline predisposition
were included as a new dedicated entity in the revision of the
WHO classification of myeloid neoplasms (Table 1), thus
acknowledging the clinical importance of recognizing these
disorders during the diagnostic work-up of patients withMN.21
Consideration of MDS or AML germline predisposition
syndromes has also been integrated in the clinical management
guidelines of patients with MDS or AML of the European
Leukemia Net and the National Comprehensive Cancer
Network.22,23 In addition, experts in this field have provided
recommendations on which patients should be investigated for
germline predisposition syndromes, and how such patients and
families should be managed.24–31 For specific disorders such as
Fanconi anaemia,32 Shwachman-Diamond syndrome,33 Dia-
mond-Blackfan anaemia,34 and telomere biology disorders35
consensus guidelines already exist, but for the other rare
disorders predisposing to MDS and AML, international
recommendations and guidelines for adult patients have not
yet been developed.36
Recognition of a specific germline predisposition in a patient
with MDS or AML is important not only for psychological
reasons providing an explanation for the disease, but also because
of clinical implications as it may tailor therapy, dictate the
selection of donor for allogeneic hematopoietic stem cell
transplantation (allo-HSCT) and determine the conditioning
regimen.37 For disorders with extra-hematopoietic manifesta-
tions, a molecular diagnosis may enable prophylactic measures,
early intervention or contribute to avoid unnecessary or even
harmful medication.38 Finally, it allows for genetic counseling
and follow-up of at-risk family members.38
The rarity of hereditary MDS and AML combined with the
heterogeneous clinical presentation makes identification of
these patients challenging. For this reason, the Nordic MDS
study group (NMDSG) decided to establish a working group
with the purpose of creating and implementing commonNordic
clinical guidelines to ensure uniformity in diagnostic procedures
and management of patients and their family members at risk.
The working group members are hematologists, pediatricians,
and clinical/medical geneticists from Sweden,Norway, Finland,
andDenmark. The initial focus of theworking groupwas on the
adult patientswithMDSorAMLand a germline predisposition,
but hopefully these guidelines may also be of value in other
settings.
This document is based on a review of the current literature
and presents the first version of Nordic recommendations for
diagnostics, surveillance and management including consider-
ations for allo-HSCT for adult patients and carriers of a
germline mutation predisposing toMDS or AML. It will be also
posted on the NMDS website (NMDS.org) and updated
regularly.2
Which patients should be tested for germline
conditions predisposing to myeloid neoplasms
Who should test patients suspected for germline
disorders
Diagnostic genetic testing for germline variants in patients with
MDS or AMLmay be performed by the clinical/medical geneticist
as part of genetic counseling or requested by a specialized
hematologist without prior referral to genetic counseling, depend-
ing on the legislation of each country. As the genetic investigation
of suspected myeloid germline disorders is challenging, close
collaboration between the hematologist who is more likely to
identify these patients and the geneticist responsible for the actual
testing, is mandatory. However, it is important that genetic
counseling is offered to all patients investigated for potential
germline conditions, even if no pathogenic variant is detected.
Genetic counseling is highly recommended prior to genetic testing
of all apparently healthy relatives for germline predisposition for
myeloid neoplasms (predictive and presymptomatic testing) includ-
ing predictive testing of HLA-identical potential family donors.Criteria for whom to test
For the development of the following criteria a number of factors
have been considered, namely:

Age
Family history Personal medical history
 Clinical/physical findings
 Genetic characterization of the clonal cells
 Recommendations published in the recent literature
 Our clinical experience thus far.
A: Patients with positive family history or signs/symptoms
indicative of a hereditary condition predisposing to myeloid
neoplasms (MN) especially MDS and AML.
A1: Patient with MDS or AML and symptoms/signs of a
hereditary condition predisposing to MN development1 diag-
nosed before the age of 50.
A2: Two individuals (first or second-degree relatives, FDR, and SDR,
respectively)withMDSorAMLor long-lasting thrombocytopenia or
symptoms/signs indicative of a hereditary condition predisposing to
MN development1, one of whom diagnosed before the age of 50.
A3: One individual with MDS or AML and two FDR or SDR
with a diagnosis of solid tumor malignancy2 one of whom
diagnosed before the age of 50.
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(2019) 3:6 www.hemaspherejournal.comA4: ≥3 FDR or SDR with MN or long-lasting thrombocytopenia
or symptoms/signs indicative of a hereditary condition predis-
posing to MN development1, independently of age.
B: Patients with MN where the diagnostic work-up for the
determination of the somatic genomic background has detected
gene variants suspected to be germline (near heterozygous or near
homozygous).
A number of genes that causes hereditary MN can also be
somatically mutated in sporadic cases. Classical examples are
variants within the RUNX1, GATA2, TP53, ETV6 and CEBPA
genes.40,41 Analysis of such variants with the advent of NGS
panels is performed routinely as part of the diagnostic work-up
for MDS and AML patients, especially in young individuals. The
Variant Allele frequency (VAF) of a specific variant detected on
the somatic NGS panel can suggest that the variant may be of
germline origin, when the VAF is 40% – 60% [near-heterozy-
gous] or >90% [near-homozygous].4,42 In such cases further
testing of extra-hematological tissue for the respective variant is
highly recommended after obtaining the patient’s consent. The
detection of a pathogenic germline variant through a somatic
gene panel is more likely in younger patients with MDS or AML
(<50 years) but may also be identified in older age groups.
Particularly, variants in the DDX41 gene are associated with
MDS andAMLbetween 55 and 65 years of age. Furthermore, the
type of variant may be of importance, for example truncating
variants in the DDX41 gene are usually of germline origin.12,13
It should be highlighted that the majority of the NGS panels
used in the current clinical setting are designed for the detection of
somatic variants, therefore a normal result does not preclude the
possibility of a germline variant in regions not included in the
actual analysis.
C: Patients not fulfilling the criteria A and B diagnosed with
MDS or AML before the age of 50 carrying aberrations of
chromosome 7 [monosomy 7/del(7q)/der(7)].
A family or personal history without any suspicion of a
hereditary disorder does not exclude an underlying predisposing
germline variant.43De novo mutations, gonadal mosaicism,
genetic reversion, variable penetrance and expressivity may
explain the absence of distinctive clinical features. It is well
established that early cancer debut strongly implies heredity.1
Several reports in the literature favor genetic testing for hereditary
conditions predisposing to MN for all young patients.5,43 That
said and for the time being, our working group proposes that
among young patients (<50 at diagnosis) without a family or
personal history only those with aberrations of chromosome 7
(monosomy 7/del(7q or other aberrations with loss of 7q
material), which is particularly common in GATA2- and
SAMD9/SAMD9L-related disorders16,17,44–46 should be further
referred for genetic counseling/testing.
Preliminary data suggest that specific somatic gene variants
may likewise be over-represented in some disorders predisposing
to MN.10,47–49 They may in the future prove to be useful
indicators to identify patients with MN who do not meet the
standard criteria for genetic testing for a predisposing germline
variant.49
We think that testing all young patients independently of
family/personal history could be performed primarily in the
context of clinical trials rather than in the clinical setting, at least
for the time being. If, however, resources are available and
national guidelines approve, genetic counseling/investigation for
MDS or AML predisposing syndromes could be offered to all
young patients.5
Limitations of the proposed criteria to take into
consideration
It is important to highlight that the current criteria are focused
mainly on known genetic predisposition syndromes to MDS or
AML. The proposed age threshold of 50 years at the time of
diagnosis is arbitrary and conditions such as predisposition to
MDS or AML due to germline DDX41 mutations13 or patients
debuting at a later age than expected may be underrepresented.
Moreover, a number of genetic aberrations predisposing to the
development of myeloid neoplasms may have not yet been
identified; therefore, some patients may not fit the aforemen-
tioned criteria. However, they may still be eligible for genetic
counseling/investigation. In case of any clinical suspicion of a
hereditary condition not included in the following criteria, a
referral to an institution with expertise in the field is
recommended.How should patients with MN and suspicion of
germline predisposition be genetically
investigated
Different approaches to genetic testing exist between the Nordic
countries and even within each country. This is primarily due to
various organizational structures and access to funding. Genetic
testing should be performed with the aim to detect both single
nucleotide variants (SNVs) and copy-number variations (CNVs).
Taking into consideration the number of the investigated genes,
comprehensive genetic analysis for these rare diseases can be only
performed with the advent of NGS, with the prerequisite that
such a technology is available in the clinical setting. It is not our
goal to provide guidelines on the actual method that should be
used, as long as the genetic testing is performed following
validated and accredited methodologies. Instead, we propose a
number of genetic conditions that should be assessed in all
patients fulfilling the abovementioned criteria (Table 1). As a
suggestion and in order to provide solid and timely genetic testing
for patients fulfilling criteria A and C we propose upfront the
performance of either whole exome sequencing (WES), whole
genome sequencing (WGS) or large NGS panels complemented
with the in silico CNV calling and/or laboratory analysis for
CNVs, such as microarrays testing or MLPA (multiplex ligation
amplification). At the moment WGS is however, not widely
established in the clinical setting, but is being investigated as an
alternative method in the Nordic countries. For the diagnostic
procedure of Fanconi anemia, telomere biology disorders,
Shwachman-Diamond syndrome, and Diamond-Blackfan ane-
mia we refer to the respective international guidelines.32–35
If a potential germline variant has been detected in a somatic
gene panel as part of the diagnostic work up for MN (see Criteria
B above), further testing of extra-hematological tissue for the
respective variant is highly recommended after obtaining the
patient’s consent. The patient may ideally be referred to genetic
counseling for further information prior to testing of extra-
hematological tissue.Diagnostic algorithm
Please see Figure 1 for a proposal for a diagnostic algorithm. It
should be highlighted that for specific syndromes such as
GATA2-related disorders and ANKDR26 even noncoding
regulatory regions should be covered. Functional analyses may
Figure 1. Diagnostic algorithm for the detection of germline variants predisposing tomyeloid neoplasms (NMs). The algorithm is adjusted depending on
the criterion which is fulfilled and aims in the detection of both single nucleotide variants (SNVs) and copy-number variations (CNVs). AML= acute myeloid leukemia;
MDS = myelodyspastic syndrome; VUS = variant of unknown significance; WES = whole exome sequencing; WGS = whole genome sequencing.
P. Baliakas et al. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adultsbe of value in Fanconi anemia, telomere biology disorders, and
Diamond-Blackfan anemia especially when a variant of uncertain
significance is detected.
Tissue for genetic testing
Regarding the tissue that should be analyzed we recommend
fibroblasts obtained after skin biopsy, especially in cases fulfilling
criteriaAandC. In selected cases otheralternatives suchasblood in
remissionmayalsobeappropriate. In cases included in criterionBa
stepwise procedure with targeted analysis of sorted T-cells isolated
from blood may be the first step. In case of confirmation of the
pathogenic variant in the T-cells, a skin biopsy should also be
performed. For carrier testing of healthy family members DNA
from a whole blood sample can be used. Carrier testing,
presymptomatic and predictive testing of healthy relatives require
genetic counseling before and after genetic testing.Genetic counseling
All patients with germline predisposition toMN should be offered
genetic counseling. This also includes patients with a positive
family history where the genetic pathogenic variant has not been
identified. If the patient has not already received genetic counseling
as part of the diagnostic procedures, it is important to offer
counseling to ensure identification of family members at risk.Surveillance of individuals with a germline
predisposition to MDS or AML
The overall goal of surveillance and monitoring of patients with a
germline predisposition to MDS and AML is to ensure
intervention prior to development of high-risk disease. However,6
uncertainty regarding penetrance and age-adjusted risk of MDS
and AML transformation makes it highly challenging to time
such intervention correctly. In addition, germline disorders
presenting as cytopenia, inherited bone marrow failure syn-
dromes (IBMFS) or MDS may benefit more from surveillance as
opposed to germline predisposition disorders presenting primar-
ily as overt AML, especially if they occur in the context of a
cancer syndrome with more than one organ involvement.
As very little evidence-based data exist on the efficacy and
benefit of surveillance in individuals with germline predisposition
to MDS and AML, published recommendations for surveillance
are solely based on expert opinion.26,28,38,44,50 For the classical
IBMFS like Fanconi anemia, Shwachman-Diamond syndrome,
Diamond-Blackfan anemia, and telomere biology disorders
guidelines for surveillance already exist and should be followed
when indicated in both children and adults.32–35,51For whom is surveillance indicated
These recommendations for surveillance are intended for: Individuals with a deleterious or likely deleterious genetic
variant associated with a germline predisposition regardless of
clinical presentation.
Individuals who fulfill the clinical diagnostic criteria for a
myeloid neoplasm with a germline predisposition even if the
pathogenic genetic variant is undetermined.
The recommendations do in general not apply to individuals
with a variant of uncertain significance (VUS) in whom clinical
diagnostic criteria for a specific predisposition disorder are absent.
If presymptomatic testing is impossible due to an unidentified
pathogenic variant, and the family history is highly suggestive of
hereditary MDS and AML, first-degree relatives to an affected
(2019) 3:6 www.hemaspherejournal.compatient may in selected cases be considered for surveillance after
genetic counseling.Surveillance and follow-up at a hematology center
with specialized expertise in disorders associated
with germline predisposition to MDS/AML
All patients including asymptomatic carriers with a germline
predisposition to MDS and AML should be referred to and
subsequently followed by a hematological center with expertise in
hereditary malignancies to ensure adequate monitoring and
tailored treatment. The hematological centre/department is
strongly recommended to collaborate closely with a clinical
geneticists/medical genetic department with expertise in diagnos-
ing and genetic counseling of hereditary haematologic disorders.
If the patient has not already received genetic counseling as part
of the diagnostic procedures, it is important to offer counseling to
ensure identification and counseling of relatives at risk.
All patients should undergo physical examination at regular
intervals, be educated about presentation and symptoms of MDS
or AML and signs of other relevant conditions, and informed of
limitations and benefits associated with surveillance.
Start of surveillance programs of asymptomatic mutation
carriers must be individualized according to the typical age of
myeloid neoplasm in the specific disorder and in the family. As
examples DDX41 associated MDS or AML presents in mid to
late adulthood13 whereas bone marrow failure syndromes
typically present in childhood.Work-up for patients with a germline
predisposition to MDS or AML
Baseline
Initially all patients should have a diagnostic work-up for MN
including a complete blood count (CBC) with manual differen-
tial, a bone marrow aspirate/biopsy with cytogenetic analysis and
testing for somatic mutations using a myeloid gene panel
according to the NMDSG guidelines. These investigations serve
to exclude MDS or a manifest bone marrow failure disorder and
as a baseline for subsequent comparison. It is important to
recognize that asymptomatic carriers may present with varying
blood counts ranging from normal CBC to mild or severe
cytopenia. Also, carriers of RUNX1, ANKRD26 and ETV6
variants may have thrombocytopenia or bleeding tendency
without thrombocytopenia at baseline.20,52–57Follow-up
At the moment it is debatable how often routine follow-up
investigations should be performed to monitor for disease
progression.Complete blood counts
The working group agreed that CBC should be repeated every 6
months particularly in high-risk patients i.e. those with pathogenic
variants in GATA2, RUNX1 or Fanconi complex genes.
If changes to abnormal values in blood counts develop, CBC
should be repeated within a few weeks, other causes of cytopenia
should be excluded, and a bone marrow biopsy/aspirate should
be performed. Even a slight drop in thrombocytes just below
normal range should warrant further investigations. See below.7
Bone marrow aspirate/biopsy
Bone marrow aspirate/biopsy should not be routinely repeated if
the CBC values are stable and other indications of progressive
disease are absent. American guidelines in children and adults
recommend annual bone marrow aspirate/biopsy in high-risk
disorders,38,50 because blood counts may not be sensitive enough
as a marker for progression. However, it is the experience of the
working group that asymptomatic carriers do not in general
consent to annual bone marrow aspirate/biopsies and that the
lack of compliance is not outweighed by the benefits of the
procedure.
If deterioration of blood counts occurs on consecutive CBC, a
bone marrow biopsy/aspirate is mandatory to examine for
changes in bone marrow cellularity, dysplasia, blast percentage,
clonal cytogenetic evolution, and somatic mutations.
Regarding clonal cytogenetic evolution it is important to note
that some acquired aberrations like monosomy 7/del(7q)/der(1;7)
and a complex karyotype are associated with high risk of
malignant transformation, whereas others do not increase
leukemic risk and can remain stable for long periods of time
or even disappear. Isochromosome 7q and del(20q) in Shwach-
man-Diamond syndrome are examples of cytogenetic aberrations
without associations to disease progression.58,59Testing of peripheral blood for somatic mutations
There was consensus in the working group about the potential
value of annual blood testing for somatic gene mutations with an
NGS gene panel targeting myeloid genes with high coverage and
reading depth. This recommendation is based on recent reports
which highlight the emergence of clonal hematopoiesis associated
with increased risk for the development of MDS or AML in
hereditary conditions, mainly those related to germline GATA2
and RUNX1 mutations.49,6,47,48 The frequency of testing for
somatic mutations and the clinical implications are however,
undefined in most other patients with germline predisposition to
MDS or AML. Nevertheless, appearance in the blood of a new
somatic mutation or a persistent or steep increase in variant allele
frequency of an already existing clone should lead to further
investigations including a bone marrow aspirate/biopsy in
exactly the same way as emerging cytopenia (see “Complete
blood count” above). The emergence of a clone should not solely
be an indication for clinical action.6 The gene, the VAF, the
number of pathogenic variants as well as the dynamics over time
should be taken into account. It should also be noted that the
above-mentionedmyeloidNGS panels are designed to include the
great majority of potential somatic genomic aberrations that
occur at the MDS or AML transformation, however they are
restricted in their targets and a normal result cannot exclude
somatic variant in genes not included in the panel-design.
For an overview of baseline and follow-up investigation of
individuals with a germline predisposition see Table 2.Management and surveillance of other organ
dysfunction
Patients with germline predisposition to MDS/AML with risk of
other organ dysfunction must be referred by the hematologist or
the clinical/medical geneticist to a hereditary cancer clinic or to
relevant medical disciplines/specialties to ensure screening for
solid tumors and organ dysfunction depending on the specific
risks and according to existing guidelines.10,32–35
Table 2
Follow-up of individuals with a germline predisposition to MDS/AML
Baseline Follow-up
Complete blood count (CBC) YES Every 6 months
Bone marrow aspirate/biopsy YES Only in case of change in CBC
NGS-myeloid gene panel YES (bone marrow) Once a yeara (blood)
Control of other relevant organs As indicated depending on the underlying condition As indicated depending on the underlying condition
CBC = complete blood count; NGS = Next-generation sequencing.
a The emergence of a clone should not solely be an indication for action. The gene, the variant allele frequency (VAF), the number of pathogenic variants as well as the dynamics over time should be taken into
account.
P. Baliakas et al. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in AdultsReferral to genetic counseling when family planning
is relevant
Patients with germline predisposition to MDS/AML should be
referred to genetic counseling when family planning is ongoing
and preferably before pregnancy. At genetic counseling the
couple should be informed about the risk in their offspring of
inheriting the predisposition and options, if any, for prenatal
diagnostics.Considerations for allo-HSCT
As the hereditary myeloid disorders are highly heterogeneous it is
outside the scope of the present guidelines to provide fully
comprehensive recommendations regarding allo-HSCT. Instead
this section contains general suggestions regarding indication,
timing, donor selection, conditioning and follow-up of allo-
HSCT for patients with “myeloid neoplasms with germline
predisposition”. Please note that especially the timing and the
indication for allo-HSCT are based on expert-opinion due to the
novelty and rarity of these syndromes.
Indication for allo-HSCT
All patients of a suitable age, who have developed MN on the
basis of a genetic predisposition except those diagnosed with
AML associated with germline variants in CEBPA, are potential
candidates for allo-HSCT (see below). It should be highlighted
that each case should be referred for discussion with an expert
transplantation panel that may include international specialists in
the field.Timing of allo-HSCT
The exact diagnosis according to the WHO 2016 classification
for myeloid neoplasms influences when allo-HSCT should be
performed.
A: Myeloid neoplasm with germline predisposition without a
pre-existing disorder or organ dysfunction
Patients with germline CEBPA mutations have no absolute
indication for allo-HSCT in CR1 because they can experience
long remissions after conventional chemotherapy,60 but the risk
of new leukemic clones is still high, therefore allo-HSCT may be
considered at some time point in these patients. AML patients
with germline DDX41 mutations are often older and no specific
recommendation regarding allo-HSCT can be made at the
moment due to lack of data.13,14
B: Myeloid neoplasm with germline predisposition and pre-
existing platelet disorder
For the time being there is no indication for allo-HSCT until the
development of a MN.8
C: Myeloid neoplasm with germline predisposition and other
organ dysfunction
These syndromes show high risk of developing MN with a
relatively early onset. Therefore, allo-HSCT could be considered
before transformation occurs to prevent mortality due to other
manifestations (GATA2 related disorders).10 In some individua-
ls, even organ dysfunctions or life-threatening immunodeficiency
may represent an indication for allo-HSCT. Timing of allo-HSCT
in patients in this subgroup must be discussed with an expert
panel that may even include international experts.Donor selection
It is crucial to refrain from using an affected family member or an
asymptomatic known carrier as donor in order to avoid graft
failure and/or donor derived leukemia.37 In families with an
identified germline predisposing pathogenic variant we recom-
mend genetic testing of any potential compatible donor in the
absence of any signs/symptoms before HSCT. The genetic testing
of a potential donor must be performed in respect of the
individual’s integrity and right “not to know” his or her carrier
status. Genetic counseling is strongly recommended before
testing if feasible. This procedure may take time, and in such
cases a well-matched unrelated donor may be first choice to avoid
harmful delay of the transplantation.
In families with a positive family history where the underlying
genetic cause has not been identified an unrelated donor may be
preferred even in the presence of phenotypically “healthy”
matching family donors. However, donor selection must depend
on availability and match.Conditioning regimen
Individuals with IBMFS, like Fanconi anemia and telomere
biology disorders, show an increased sensitivity to chemotherapy
and specific dose-reduced conditioning regimens are recom-
mended (for more information please see the respective treatment
recommendations).32,35,51
Reduced intensity conditioning transplantation can also be
used for patients with GATA2 related syndromes before they
have transformed because functional and numeric defects in the
immune and hematopoietic stem cells will allow it.61Follow up after allo-HSCT
Allo-HSCT increases the risk for secondary tumors, but many
patients within the category “myeloid neoplasm with genetic
predisposition and other organ dysfunction” have a specifically
high risk so they should be monitored even more closely after
allo-HSCT (Table 1).32–35 See Table 1.
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(2019) 3:6 www.hemaspherejournal.comConcluding remarks
Germline predisposition to myeloid neoplasms is a new and
rapidly emerging field, which significantly impacts therapy and
care of involved patients and family members. Hence it is crucial
that hematologists and clinical/medical geneticists have the basic
knowledge to suspect a germline disorder. These Nordic
guidelines are intended to support clinicians when dealing with
patients with a potential germline predisposition to MDS or
AML. The working group is aware that the criteria for genetic
testing are conservative reflecting the fact that genetic testing is
not widely available in all Nordic countries. However, this
approach is aimed at identifying highly penetrant germline
disorders, and as mentioned above the recommendations need to
be updated and revised regularly.
At present we lack understanding on many biological and
clinical aspects of the well-known and new germline disorders
with increased risk of MDS or AML. Joint research projects and
registries are urgently needed, and we strongly encourage
hematologists and clinical/medical geneticists with special
interest and expertise in the field to actively take part in such
research activities.Acknowledgment
The authors would like to thank the Nordic MDS study group
(NMDSG) for providing the forum within which this manuscript
was prepared.References
1. Huang KL, Mashl RJ, Wu Y, et al. Pathogenic Germline Variants in
10,389 Adult Cancers. Cell. 2018;173:355–370. e314.
2. Lu C, Xie M, Wendl MC, et al. Patterns and functional implications of
rare germline variants across 12 cancer types. Nat Commun.
2015;6:10086.
3. Wartiovaara-Kautto U, Hirvonen EAM, Pitkanen E, et al. Germline
alterations in a consecutive series of acute myeloid leukemia.
Leukemia. 2018;32:2282–2285.
4. Drazer MW, Kadri S, Sukhanova M, et al. Prognostic tumor sequencing
panels frequently identify germ line variants associated with hereditary
hematopoietic malignancies. Blood Adv. 2018;2:146–150.
5. Tawana K, Drazer MW, Churpek JE. Universal genetic testing for
inherited susceptibility in children and adults with myelodysplastic
syndrome and acute myeloid leukemia: are we there yet? Leukemia.
2018;32:1482–1492.
6. Al Seraihi AF, Rio-Machin A, Tawana K, et al. GATA2 monoallelic
expression underlies reduced penetrance in inherited GATA2-mutated
MDS/AML. Leukemia. 2018.
7. Green CL, Tawana K, Hills RK, et al. GATA2 mutations in sporadic and
familial acute myeloid leukaemia patients with CEBPA mutations. Br J
Haematol. 2013;161:701–705.
8. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency
caused by mutations in a conserved intronic element leads to
MonoMAC syndrome. Blood. 2013;121:3830–3837. S3831-3837.
9. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2
cause primary lymphedema associated with a predisposition to acute
myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43:929–931.
10. Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related
myeloid neoplasms. Semin Hematol. 2017;54:81–86.
11. Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical
characteristics, and prognosis of GATA2-related myelodysplastic
syndromes in children and adolescents. Blood. 2016;127:1387–
1397. quiz 1518.
12. Lewinsohn M, Brown AL, Weinel LM, et al. Novel germ line DDX41
mutations define families with a lower age of MDS/AML onset and
lymphoid malignancies. Blood. 2016;127:1017–1023.
13. Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic
defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:
658–670.9
counting. Blood. 2016;127:960–961.
15. Jeffries L, Shima H, Ji W, et al. A novel SAMD9 mutation causing
MIRAGE syndrome: An expansion and review of phenotype, dysmor-
phology, and natural history. Am J Med Genet A. 2018;176:415–420.
16. Narumi S, Amano N, Ishii T, et al. SAMD9 mutations cause a novel
multisystem disorder, MIRAGE syndrome, and are associated with loss
of chromosome 7. Nat Genet. 2016;48:792–797.
17. Tesi B, Davidsson J, Voss M, et al. Cytopenia, predisposition to
myelodysplastic syndrome, immunodeficiency, and neurological dis-
ease caused by gain-of-function SAMD9L mutations is frequently
ameliorated by hematopoietic revertant mosaicism. Blood. 2016;128:
18. Moriyama T, Metzger ML, Wu G, et al. Germline genetic variation in
ETV6 and risk of childhood acute lymphoblastic leukaemia: a
systematic genetic study. Lancet Oncol. 2015;16:1659–1666.
19. Poggi M, Canault M, Favier M, et al. Germline variants in ETV6 underlie
reduced platelet formation, platelet dysfunction and increased levels of
circulating CD34+ progenitors. Haematologica. 2017;102:282–294.
20. Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in
familial thrombocytopenia and hematologic malignancy. Nat Genet.
2015;47:180–185.
21. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World
Health Organization classification of myeloid neoplasms and acute
leukemia. Blood. 2016;127:2391–2405.
22. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of
AML in adults: 2017 ELN recommendations from an international expert
panel. Blood. 2017;129:424–447.
23. Guidelines. NCCN. Available at: https://www.nccn.org/professionals/
physician_gls/pdf/mds.pdf. Accessed August 27 2019.
24. Brown AL, Churpek JE, Malcovati L, et al. Recognition of familial
myeloid neoplasia in adults. Semin Hematol. 2017;54:60–68.
25. Churpek JE. Familial myelodysplastic syndrome/acute myeloid leuke-
mia. Best Pract Res Cl Ha. 2017;30:287–289.
26. Churpek JE, Lorenz R, Nedumgottil S, et al. Proposal for the clinical
detection and management of patients and their family members with
familial myelodysplastic syndrome/acute leukemia predisposition
syndromes. Leuk Lymphoma. 2013;54:28–35.
27. Churpek JE, Nickels E, Marquez R, et al. Identifying familial myelodys-
plastic/acute leukemia predisposition syndromes through hematopoi-
etic stem cell transplantation donors with thrombocytopenia. Blood.
2012;120:5247–5249.
28. Furutani E, Shimamura A. Germline genetic predisposition to
hematologic malignancy. J Clin Oncol. 2017;35:1018–1028.
29. Liew E, Owen C. Familial myelodysplastic syndromes: a review of the
literature. Haematologica. 2011;96:1536–1542.
30. University of Chicago Hematopoietic Malignancies Cancer Risk T. How
I diagnose and manage individuals at risk for inherited myeloid
malignancies. Blood. 2016;128:1800–1813.
31. West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/
acute leukemia syndromes: a review and utility for translational
investigations. Ann Ny Acad Sci. 2014;1310:111–118.
32. Fund. FAR. Available at: https://www.fanconi.org/images/uploads/
other/FARF_Guidelines_Book_interior_lo-res.pdf. Accessed 2014.
33. Dror Y, Donadieu J, Koglmeier J, et al. Draft consensus guidelines for
diagnosis and treatment of Shwachman-Diamond syndrome. Ann N Y
Acad Sci. 2011;1242:40–55.
34. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond
Blackfan anaemia: results of an international clinical consensus
conference. Br J Haematol. 2008;142:859–876.
35. Teamtelomere. Available at: https://teamtelomere.org/wp-content/
uploads/2018/07/DC-TBD-Diagnosis-And-Management-Guidelines.
pdf. Accessed 2015.
36. Walsh MF, Chang VY, Kohlmann WK, et al. Recommendations for
childhood cancer screening and surveillance in DNA repair disorders.
Clin Cancer Res. 2017;23:e23–e31.
37. Galera P, Hsu AP, Wang W, et al. Donor-derived MDS/AML in families
with germline GATA2 mutation. Blood. 2018;132:1994–1998.
38. Godley LA, Shimamura A. Genetic predisposition to hematologic
malignancies: management and surveillance.Blood. 2017;130:424–432.
39. Rojek K, Nickels E, Neistadt B, et al. Identifying inherited and acquired
genetic factors involved in poor stem cell mobilization and donor-
derived malignancy. Biol Blood Marrow Tr. 2016;22:2100–2103.
40. Papaemmanuil E, Dohner H, Campbell PJ. Genomic classification in
acute myeloid leukemia. N Engl J Med. 2016;375:900–901.
41. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification
and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:
2209–2221.
42. Yannakou CK, Jones K, Ryland GL, et al. Incidental detection of 52. Beri-Dexheimer M, Latger-Cannard V, Philippe C, et al. Clinical
P. Baliakas et al. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adultsgermline variants of potential clinical significance by massively parallel
sequencing in haematological malignancies. J Clin Pathol. 2018;71:
84–87.
43. Zhang JH, Walsh MF, Wu G, et al. Germline mutations in
predisposition genes in pediatric cancer. New Engl J Med.
2015;373:2336–2346.
44. Babushok DV, Bessler M, Olson TS. Genetic predisposition to
myelodysplastic syndrome and acute myeloid leukemia in children
and young adults. Leuk Lymphoma. 2016;57:520–536.
45. Bluteau O, Sebert M, Leblanc T, et al. A landscape of germ line
mutations in a cohort of inherited bone marrow failure patients. Blood.
2018;131:717–732.
46. Davidsson J, Puschmann A, Tedgard U, et al. SAMD9 and SAMD9L in
inherited predisposition to ataxia, pancytopenia, and myeloid malig-
nancies. Leukemia. 2018;32:1106–1115.
47. Churpek JE, Pyrtel K, Kanchi KL, et al. Genomic analysis of germ line
and somatic variants in familial myelodysplasia/acute myeloid leuke-
mia. Blood. 2015;126:2484–2490.
48. Wang X, Muramatsu H, Okuno Y, et al. GATA2 and secondary
mutations in familial myelodysplastic syndromes and pediatric myeloid
malignancies. Haematologica. 2015;100:e398–e401.
49. West RR, Hsu AP, Holland SM, et al. Acquired ASXL1 mutations are
common in patients with inherited GATA2 mutations and correlate with
myeloid transformation. Haematologica. 2014;99:276–281.
50. Porter CC, Druley TE, Erez A, et al. Recommendations for surveillance
for children with leukemia-predisposing conditions. Clin Cancer Res.
2017;23:e14–e22.
51. Alter BP. Inherited bone marrow failure syndromes: considerations pre-
and posttransplant. Blood. 2017;130:2257–2264.10phenotype of germline RUNX1 haploinsufficiency: from point mutations
to large genomic deletions. Eur J Hum Genet. 2008;16:1014–1018.
53. Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited
RUNX1 mutations causing familial platelet disorder with propensity to
myeloid malignancy. Blood. 2008;112:4639–4645.
54. Preudhomme C, Renneville A, Bourdon V, et al. High frequency of
RUNX1 biallelic alteration in acute myeloid leukemia secondary to
familial platelet disorder. Blood. 2009;113:5583–5587.
55. Ripperger T, Tauscher M, Haase D, et al. Managing individuals with
propensity to myeloid malignancies due to germline RUNX1 deficiency.
Haematologica. 2011;96:1892–1894.
56. Topka S, Vijai J, Walsh MF, et al. Germline ETV6 mutations confer
susceptibility to acute lymphoblastic leukemia and thrombocytopenia.
PLoS Genet. 2015;11:e1005262.
57. Noris P, Favier R, Alessi MC, et al. ANKRD26-related thrombocytopenia
and myeloid malignancies. Blood. 2013;122:1987–1989.
58. Minelli A, Maserati E, Nicolis E, et al. The isochromosome i(7)(q10)
carrying c.258+2t>c mutation of the SBDS gene does not promote
development of myeloid malignancies in patients with Shwachman
syndrome. Leukemia. 2009;23:708–711.
59. Pressato B, Valli R,Marletta C, et al. Deletion of chromosome 20 in bone
marrow of patients with Shwachman-Diamond syndrome, loss of the
EIF6 gene and benign prognosis. Br J Haematol. 2012;157:503–505.
60. Tawana K, Wang J, Renneville A, et al. Disease evolution and outcomes
in familial AML with germline CEBPA mutations. Blood. 2015;126:1214–
1223.
61. Grossman J, Cuellar-Rodriguez J, Gea-Banacloche J, et al. Non-
myeloablative allogeneic hematopoietic stem cell transplantation for
GATA2 deficiency. Biol Blood Marrow Transplant. 2014;20:1940–1948.
